Tìm theo
Ofloxacin
Các tên gọi khác (5 ) :
  • 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
  • Ofloxacine
  • Ofloxacino
  • Ofloxacinum
  • OFLX
Thuốc dùng điều trị mắt, tai mũi họng
Thuốc Gốc
Small Molecule
CAS: 82419-36-1
ATC: J01MA01, S01AE01, S02AA16
ĐG : Akorn Inc. , http://www.akorn.com
CTHH: C18H20FN3O4
PTK: 361.3675
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C18H20FN3O4
Phân tử khối
361.3675
Monoisotopic mass
361.143784348
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChI Key
InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N
IUPAC Name
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Traditional IUPAC Name
ofloxacin
SMILES
CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
Độ tan chảy
254 dec °C
Độ hòa tan
28.3 mg/mL
logP
-0.39
logS
-2.4
pKa (strongest acidic)
5.45
pKa (Strongest Basic)
6.2
PSA
73.32 Å2
Refractivity
94.94 m3·mol-1
Polarizability
36.69 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
7
H Bond Donor Count
1
Physiological Charge
-1
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Cơ Chế Tác Dụng : A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem] Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.
Dược Động Học :
▧ Absorption :
Bioavailability of ofloxacin in the tablet formulation is approximately 98%
▧ Protein binding :
32%
▧ Metabolism :
Hepatic
▧ Route of Elimination :
Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.
▧ Half Life :
9 hours
Độc Tính : LD50=5450 mg/kg (orally in mice)
Chỉ Định : For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Tương Tác Thuốc :
  • Acenocoumarol The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol.
  • Aluminium Formation of non-absorbable complexes
  • Anisindione The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione.
  • Calcium Formation of non-absorbable complexes
  • Calcium Acetate Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
  • Dicoumarol The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol.
  • Dihydroquinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
  • Foscarnet Increased risk of convulsions
  • Iron Formation of non-absorbable complexes
  • Iron Dextran Formation of non-absorbable complexes
  • Magnesium Formation of non-absorbable complexes
  • Magnesium oxide Formation of non-absorbable complexes
  • Procainamide Ofloxacin may increase the effect of procainamide.
  • Quinidine Increased risk of cardiotoxicity and arrhythmias
  • Quinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
  • Sucralfate Formation of non-absorbable complexes
  • Tacrine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed.
  • Thiothixene The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed.
  • Tizanidine Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
  • Warfarin The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.
  • Zinc Formation of non-absorbable complexes
Liều Lượng & Cách Dùng : Liquid - Ophthalmic
Solution - Ophthalmic
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Floxin
  • Công ty :
    Sản phẩm biệt dược : Floxstat
  • Công ty :
    Sản phẩm biệt dược : Ocuflox
  • Công ty :
    Sản phẩm biệt dược : Zanocin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01165
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4583
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507574
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07321
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00453
ChemSpider
http://www.chemspider.com/Chemical-Structure.4422.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0062-1542-01
PharmGKB
http://www.pharmgkb.org/drug/PA450684
Wikipedia
http://en.wikipedia.org/wiki/Ofloxacin
RxList
http://www.rxlist.com/cgi/generic/oflox.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/flo1181.shtml
Drugs.com
http://www.drugs.com/cdi/ofloxacin-drops.html
... loading
... loading